SCHEMBL29700581

SCHEMBL29700581

NC(=O)NCCCC(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CA3 P07451 2/20 0.38
CA5A P35218 2/20 0.38
CA5B Q9Y2D0 2/20 0.38
CA12 O43570 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
EPHX1 P07099 1/20 0.35
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7935563 0.86 CFTR (0.37) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL5405580 0.81 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL5620319 0.79 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL26066649 0.78 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL10323553 0.77 SMN1; SMN2 (0.44) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL13046403 0.77 MAOA (0.36) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL10061687 0.77 KDM4E (0.58) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL1837224 0.77 KDM4E (0.48) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL1309431 0.77 TDP1 (0.42) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL21678029 0.76 GRM4 (0.35) ALDH1A1SMN1; SMN2POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028333-A1 NEW COMPOUNDS VICORE PHARMA AB (SE) 2026-01-29 US claimed
US-20220388994-A1 NEW COMPOUNDS VICORE PHARMA AB (SE) 2022-12-08 US claimed
EP-4031240-A1 NEW COMPOUNDS Vicore Pharma AB (SE) 2022-07-27 EP claimed
CN-114786774-A Novel compounds 维科尔药物公司 2022-07-22 CN claimed
US-20260028333-A1 NEW COMPOUNDS VICORE PHARMA AB (SE) 2026-01-29 US disclosed
US-20220388994-A1 NEW COMPOUNDS VICORE PHARMA AB (SE) 2022-12-08 US disclosed
EP-4031240-A1 NEW COMPOUNDS Vicore Pharma AB (SE) 2022-07-27 EP disclosed
CN-114786774-A Novel compounds 维科尔药物公司 2022-07-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028333-A1 NEW COMPOUNDS AGTR1, AGTR2, REN ALDH1A1 2909/4885SMN1; SMN2 4062/4885POLB 3666/4885
US-20220388994-A1 NEW COMPOUNDS RXFP3, RXFP4, RXFP1 ALDH1A1 2970/4885SMN1; SMN2 4226/4885POLB 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.